

Clinical Trial Protocol

Iranian Registry of Clinical Trials

13 Jun 2026

The role of synbiotic in the prevention of necrotizing enterocolitis in preterm neonates.

Protocol summary

Study aim

Investigate the effect of synbiotic on breast feeding tolerance in preterm neonate and the age of the full oral nutrition and necrotizing enterocolitis amount.

Design

This is a randomized, double-blind, placebo-controlled study. 118 preterm infants are randomly divided into two equal groups. neonates in the first group will receive 1/25 cc/kg/ day oral synbiotic, and the second group will receive 1/25 cc/kg/day distilled water as placebo. In both groups, in case of pre-daily milk intake tolerance, milk intake will increase by 20 cc/kg/day and before and after the intervention, some factors will be recorded including the time to reach full oral nutrition, duration of hospitalization, weight of discharge, status of necrotizing enterocolitis and its severity, and neonate mortality.

Settings and conduct

The study was performed in Imam Reza Hospital in Kermanshah after obtaining written consent from parents by a randomized, double-blind manner. The researcher, patients, and parents are unaware of the type of prescription drug.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Gestational age less than 34 weeks, elapse of maximum 28 days after birth, birth weight 1000 to 1500 gr. Exclusion criteria: Certain and chronic diseases

Intervention groups

1/25 cc/kg/day oral synbiotic in treatment group. 1/25 cc/kg/day distilled water as placebo in control group (placebo sachet with the same shape and color to synbiotic)

Main outcome variables

The breast milk tolerance
The rate of Necrotizing enterocolitis
The age of the full oral nutrition

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20180519039715N2**

Registration date: **2019-10-06, 1398/07/14**

Registration timing: **retrospective**

Last update: **2019-10-06, 1398/07/14**

Update count: **0**

Registration date

2019-10-06, 1398/07/14

Registrant information

Name

Sara Hookari

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 83 3826 4513

Email address

s.hookari@kums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2018-09-23, 1397/07/01

Expected recruitment end date

2019-09-22, 1398/06/31

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The role of synbiotic in the prevention of necrotizing enterocolitis in preterm neonates.

Public title

The role of synbiotic in the prevention of necrotizing enterocolitis in preterm neonates.

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Admission to the Neonatal Intensive Care Unit (NICU) at birth Gestational age less than 34 weeks (early preterm) Elapse of maximum 28 days after birth birth weight 1000 to 1500 gr Lack of affliction with gastrointestinal obstruction, amphalocele, gastroschis, congenital heart disease, clinical or proven sepsis, grade 2 and 3 asphyxia No history of immunodeficiency among relatives No maternal drug addiction Avoidance of breast-feeding to feed neonate Avoidance of synbiotic supplementation consumption by the infant mother

Exclusion criteria:

Gestational age over 34 weeks Elapse of over 28 days since the birth of infant Birth weight less than 1000 (due to high mortality rates) and more than 1500 gr Neonate's affliction with gastrointestinal obstruction, amphalocele, gastroschis, congenital heart diseases, clinical or proven sepsis, grade 2 and grade 3 asphyxia History of immunodeficiency among relatives Neonate with addicted mother Babies fed with powdered milk Oral administration of synbiotic supplement by neonate's mother

Age

From **1 day** old to **28 days** old

Gender

Both

Phase

1

Groups that have been masked

- Participant
- Investigator
- Outcome assessor
- Data analyser

Sample size

Target sample size: **118**

Randomization (investigator's opinion)

Randomized

Randomization description

Randomization was performed by assigning one to one according to the neonatal medical record number. The neonate with the even case number were assigned to the intervention group and the neonate with the odd case number were assigned to the placebo group.

Blinding (investigator's opinion)

Double blinded

Blinding description

In this study, the parents of the participants were blind and unaware of the type of drug (synbiotic or placebo).The main researcher is blind. One of the staff is responsible for prescribing and secretly prescribing the drug and the resident and the other nurse are responsible for data collection.The data analyzer also announces the results in groups A and B. The efficacy evaluator is also unaware of the type of medication

prescribed for each patient.

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Kermanshah University of Medical Sciences

Street address

Building No.2, Shahid Beheshti Blvd, Vice Chancellor for Research Affairs, Kermanshah University of Medical Sciences Kermanshah

City

Kermanshah

Province

Kermanshah

Postal code

6719851115

Approval date

2018-03-14, 1396/12/23

Ethics committee reference number

IR.KUMS.REC.1396.702

Health conditions studied

1

Description of health condition studied

Necrotizing enterocolitis

ICD-10 code

P77

ICD-10 code description

Necrotizing enterocolitis of newborn

Primary outcomes

1

Description

Duration to reach full oral nutrition (150 cc/kg/day)

Timepoint

Measuring the time from birth to reach the age of full oral nutrition (150 cc/kg/day)

Method of measurement

Asking parents

2

Description

Breast feeding tolerance

Timepoint

Measuring the amount of breast milk consumed per day and then daily until discharge

Method of measurement

Asking parents

3

Description

Necrotizing enterocolitis

Timepoint

Measurement from birth to discharge and daily

Method of measurement

Stage 1 (suspicion to enterocolitis): The symptoms include apnea, lethargy, bloody stool, abdominal distension, temperature instability, the residue in the stomach, lack of radiologic evidence. Stage 2 (proven enterocolitis): Symptoms of stage 1 + thrombocytopenia ± mild metabolic acidosis, abdominal tenderness, and presence of pneumatosis or gas in the portal vein. Stage 3 (advanced enterocolitis): Symptoms of stage 2 + hypotension, bradycardia, severe apnea, metabolic and respiratory acidosis, diffuse intravascular coagulation, clear abdominal tenderness, neutropenia, pneumoperitonitis.

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: 1/25 cc/kg/day oral synbiotic (Made by bio-fermentation Co. in IRI, 1/25 cc synbiotic combination consisting of probiotic compounds contains Lactobacillus reuteri 4*10⁸ CFU, Lactobacillus rhamnosus 2*10⁹ CFU, Bifidobacterium infantis 3*10⁸ CFU and prebiotic compounds including Fructooligosaccharides (FOS) 3% and other ingredients including Sunflower oil, MCT oil (Medium-chain triglycerides), Silicon dioxide (SiO₂) and Natural flavor).

Category

Prevention

2

Description

Control group: 1/25 cc/kg/day oral distilled water as placebo (placebo sachet with the same shape and color to symbiotic).

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Imam Reza Hospital

Full name of responsible person

Dr. Ali Soroush

Street address

Bagh Abrisham Blvd, Imam Reza Hospital

City

Kermanshah

Province

Kermanshah

Postal code

6719851451

Phone

+98 83 3826 4513

Email

Ali.Soroush@Kums.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Kermanshah University of Medical Sciences

Full name of responsible person

Korosh Hamzehee

Street address

Building No.2, Shahid Beheshti Blvd, Vice Chancellor for Research Affairs, Kermanshah University of Medical Sciences Kermanshah

City

Kermanshah

Province

Kermanshah

Postal code

6714697956

Phone

+98 83 3836 0014

Email

khamzehee@Kums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Kermanshah University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Kermanshah University of Medical Sciences

Full name of responsible person

Amir Shahidolahi

Position

Medical doctor

Latest degree

Bachelor

Other areas of specialty/work

Pediatrics

Street address

Bagh Abrisham Blvd, Imam Reza Hospital

City

Kermanshah

Province

Kermanshah

Postal code

6719851451

Phone

+98 83 3826 4513

Email

d.p_2011@yahoo.com

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Kermanshah University of Medical Sciences

Full name of responsible person

Homa Babaei

Position

Professor

Latest degree

Subspecialist

Other areas of specialty/work

Pediatrics

Street address

Bagh Abrisham Blvd, Imam Reza Hospital

City

Kermanshah

Province

Kermanshah

Postal code

6719751451

Phone

+98 83 3826 4513

Email

Homa_babaei@Kums.ac.ir

Person responsible for updating data**Contact****Name of organization / entity**

Kermanshah University of Medical Sciences

Full name of responsible person

Sara Hookari

Position

Researcher

Latest degree

Master

Other areas of specialty/work

Biostatistics

Street address

Isar Square, Farabi Hospital

City

Kermanshah

Province

Kermanshah

Postal code

6714697956

Phone

+98 83 3835 0121

Email

sara_hoo64@yahoo.com

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

Adherence to study ethical standards

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available